Ascendis Pharma A/S at JPMorgan Healthcare Conference (Virtual) Transcript
Great. Good morning, everyone. My name is Jess Fye. I'm one of the Senior Biotech analysts at JPMorgan. And we're continuing the health care conference this morning with Ascendis. I'm joined by the company's CEO, Jan Mikkelsen, who's going to give a presentation. And to the extent there's time for Q&A at the end, you can submit questions to me on the portal by using the blue, ask a question, button.
But without further ado, let me turn it over to Jan.
/- -
So first, thank you a lot, Jess. And thank you to everyone for joining here today to hear about Ascendis.
And as a reminder, Slide 2, I will make forward-looking statement. Please refer to our SEC filing for associated risk factors.
So now I move to Slide 3. Yes, not as a big surprise. We are really sticking to our visions, our strategy. What we all are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
